Results 141 to 150 of about 6,071 (199)
RSV Prevention in Infants and Young Children. [PDF]
Am J Respir Crit Care MedCacho F, Sockrider M.
europepmc +1 more source
Clesrovimab approval for RSV: a lifesaving opportunity for global infant health equity. [PDF]
Ann Med Surg (Lond)Kumari S, Kamil KA.
europepmc +1 more source
Respiratory syncytial virus immunization in children: The old, the new and what's just around the corner. [PDF]
Hum Vaccin ImmunotherPaes BA +4 more
europepmc +1 more source
Virus-like Particle Vaccines Containing RSV Fusion Protein Cleavage Mutations Are Immunogenic and Protective in Cotton Rats With a Prime Dose. [PDF]
Immune NetwHwang HS +6 more
europepmc +1 more source
Improving the prescribing of palivizumab
Journal of Paediatrics and Child Health, 2018 AimPalivizumab prevents respiratory syncytial virus (RSV) in children at high risk of severe disease. This paper reviews the use and effectiveness of palivizumab at two tertiary paediatric hospitals (hospitals A and B) in New South Wales, Australia.MethodsChildren prescribed palivizumab during the pre‐intervention period, 1 January 2013 until 31 ...
Simone Trist +4 more
openaire +3 more sources
Cost‐effectiveness of palivizumab in New Zealand
Journal of Paediatrics and Child Health, 2002 Objective: To establish the preterm infant hospitalization risks from respiratory syncytial virus (RSV) in New Zealand and the net cost per hospitalization averted by palivizumab.Methods: The 437 infants born < 32 weeks gestation in 1997 and treated at five major neonatal units were identified.
Vogel, AM +9 more
openaire +6 more sources
Pediatric Pulmonology, 2016 Respiratory syncytial virus infection represents a clinical burden among young children under 24 months. Palivizumab is the only drug licensed in Italy for the prevention of serious lower respiratory tract disease requiring hospitalization caused by ...
Maria Serenella Pignotti +2 more
exaly +3 more sources